Glucagon supports postabsorptive plasma glucose concentrations in humans with biologically optimal insulin levels

Diabetes

Volumn 59, Issue 11, 2010, Pages 2941-2944

  Cooperberg, Benjamin A ^a   Cryer, Philip E ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON; GLUCOSE; GROWTH HORMONE; INSULIN; OCTREOTIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HORMONE ACTION; HUMAN; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN TREATMENT; MALE; PRIORITY JOURNAL;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; FEMALE; GLUCAGON; HUMANS; INFUSIONS, INTRAVENOUS; INSULIN; INTESTINAL ABSORPTION; MALE; REFERENCE VALUES;

EID: 78049318515     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db10-0750     Document Type: Article

References (22)

1. Unger RH, Orci L. Glucagon and the A cell: physiology and pathophysiology (first of two parts). N Engl J Med 1981;304:1518-1524 (Pubitemid 11065936)
2. Unger RH, Orci L. Glucagon and the A cell: physiology and pathophysiology (second of two parts). N Engl J Med 1981;304:1575-1580 (Pubitemid 11122505)
3. Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2000;85:4053-4059
4. Dunning BE, Gerich JE. The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr Rev 2007;28:253-283
5. Cherrington AD. Control of glucose production in vivo by insulin and glucagon. In Handbook of Physiology. Sect. 7, The Endocrine System, volume 2, The Endocrine Pancreas and the Regulation of Metabolism. Jefferson LS, Cherrington AD, Eds. New York, Oxford University Press 2001, p. 759-785
6. Krentz AJ, Boyle PJ, Macdonald LM, Schade DS. Octreotide: a long-acting inhibitor of endogenous hormone secretion for human metabolic investigations. Metabolism 1994;43:24-31
7. Liljenquist JE, Mueller GL, Cherrington AD, Keller U, Chiasson J-L, Perry JM, Lacy WW, Rabinowitz D. Evidence for an important role of glucagon in the regulation of hepatic glucose production in normal man. J Clin Invest 1977;59:369-374
8. Sherwin RS, Hendler R, DeFronzo R, Wahren J, Felic P. Glucose homeostasis during prolonged suppression of glucagon and insulin secretion by somatostatin. Proc Natl Acad Sci U S A 1977;74:348-352 (Pubitemid 8025851)
9. Lins PE, Efendić S. Hyperglycemia induced by somatostatin in normal subjects. Horm Metab Res 1976;8:497-498
10. Rosen SG, Clutter WE, Shah SD, Miller JP, Bier DM, Cryer PE. Direct alpha-adrenergic stimulation of hepatic glucose production in human subjects. Am J Physiol 1983;245:E616-E626
11. Breckenridge SM, Raju B, Arbelaez AM, Patterson BW, Cooperberg BA, Cryer PE. Basal insulin, glucagon, and growth hormone replacement. Am J Physiol Endocrinol Metab 2007;293:E1303-E1310
12. Breckenridge SM, Cooperberg BA, Arbelaez AM, Patterson BW, Cryer PE. Glucagon, in concert with insulin, supports the postabsorptive plasma glucose concentration in humans. Diabetes 2007;56:2442-2448
13. Nielsen MF, Nyholm B, Caumo A, Chandramouli V, Schumann WC, Cobelli C, Landau BR, Rizza RA, Schmitz O. Prandial glucose effectiveness and fasting gluconeogenesis in insulin-resistant first-degree relatives of patients with type 2 diabetes. Diabetes 2000;49:2135-2141
14. Rosen SG, Clutter WE, Berk MA, Shah SD, Cryer PE. Epinephrine supports the postabsorptive plasma glucose concentration and prevents hypoglycemia when glucagon secretion is deficient in man. J Clin Invest 1984;73:405-411
15. Nielsen MF, Basu R, Wise S, Caumo A, Cobelli C, Rizza RA. Normal glucose-induced suppression of glucose production but impaired stimulation of glucose disposal in type 2 diabetes: evidence for a concentration-dependent defect in uptake. Diabetes 1998;47:1735-1747
16. Gerich JE, Lorenzi M, Bier DM, Tsalikian E, Schneider V, Karam JH, Forsham PH. Effects of physiologic levels of glucagon and growth hormone on human carbohydrate and lipid metabolism. Studies involving administration of exogenous hormone during suppression of endogenous hormone secretion with somatostatin. J Clin Invest 1976;57:875-884
17. Shah SD, Clutter WE, Cryer PE. External and internal standards in the single-isotope derivative (radioenzymatic) measurement of plasma norepinephrine and epinephrine. J Lab Clin Med 1985;106:624-629
18. Lins PE, Wajngot A, Adamson U, Vranic M, Efendić S. Minimal increases in glucagon levels enhance glucose production in man with partial hypoinsulinemia. Diabetes 1983;32:633-636
19. Ward WK, Best JD, Halter JB, Porte D Jr. Prolonged infusion of somatostatin with glucagon replacement increases plasma glucose and glucose turnover in man. J Clin Endocrinol Metab 1984;58:449-453
20. DeFronzo RA, Hendler R, Simonson D. Insulin resistance is a prominent feature of insulin-dependent diabetes. Diabetes 1982;31:795-801
21. DeFronzo RA, Simonson D, Ferrannini E. Hepatic and peripheral insulin resistance: a common feature of type 2 (non-insulin-dependent) and type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1982;23:313-319 (Pubitemid 12020666)
22. Pang TT, Narendran P. Addressing insulin resistance in type 1 diabetes. Diabet Med 2008;25:1015-1024